Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003352 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
A Phase 2 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00003352: Completed Phase 2 study, sponsored by NSABP Foundation.
NCT00003352 is a Phase 2 study that has completed, run by NSABP Foundation. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003352, a Phase 2 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide, and docetaxel in treating women with stage IIIB or stage IV breast cancer.
Interventions
- DRUG Taxotere
- DRUG cyclophosphamide
- DRUG Adriamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1998-06 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00003352 record still lists
NCT00003352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which Taxotere is the first listed.
NCT00003352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003352 about?
NCT00003352 is a clinical study titled "Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of doxorubicin, cyclophosphamide,...
What is the current status of trial NCT00003352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 1998-06. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00003352?
The interventions under investigation include: Taxotere (DRUG), cyclophosphamide (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT00003352?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003352's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia